P. Emery, F. Breedveld, and M. Dougados, Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide, Annals of the Rheumatic Diseases, vol.61, issue.4, pp.290-297, 2002.
DOI : 10.1136/ard.61.4.290

J. Smolen, R. Landewé, and F. Breedveld, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Annals of the Rheumatic Diseases, vol.69, issue.(Suppl), pp.492-509, 2014.
DOI : 10.1136/annrheumdis-2013-204573

C. Gaujoux-viala, L. Gossec, and A. Cantagrel, Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis, Joint Bone Spine, vol.81, issue.4, pp.287-97, 2014.
DOI : 10.1016/j.jbspin.2014.05.002

C. Grigor, H. Capell, and A. Stirling, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial, The Lancet, vol.364, issue.9430, pp.263-272, 2004.
DOI : 10.1016/S0140-6736(04)16676-2

J. Smolen, D. Aletaha, and J. Bijlsma, Treating rheumatoid arthritis to target: recommendations of an international task force, Annals of the Rheumatic Diseases, vol.69, issue.4, pp.631-638, 2010.
DOI : 10.1136/ard.2009.123919

C. Lukas, B. Combe, and P. Ravaud, Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the ??tude et Suivi des Polyarthrites Indiff??Renci??es r??centes (Study and Followup of Early Undifferentiate, Arthritis & Rheumatism, vol.31, issue.7, pp.1804-1815, 2011.
DOI : 10.1002/art.30371

M. Schoels, R. Knevel, and D. Aletaha, Evidence for treating rheumatoid arthritis to target: results of a systematic literature search, Annals of the Rheumatic Diseases, vol.69, issue.4, pp.638-681, 2010.
DOI : 10.1136/ard.2009.123976

L. Loët, X. Berthelot, J. Cantagrel, and A. , Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology, Annals of the Rheumatic Diseases, vol.65, issue.1, pp.45-50, 2006.
DOI : 10.1136/ard.2005.035436

C. Gaujoux-viala, N. J. Ramiro, and S. , Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.52, issue.(Suppl 10), pp.510-525, 2014.
DOI : 10.1136/annrheumdis-2013-204588

M. Boers, A. Verhoeven, and H. Markusse, Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis, The Lancet, vol.350, issue.9074, pp.309-327, 1997.
DOI : 10.1016/S0140-6736(97)01300-7

L. Moreland, O. Dell, J. Paulus, and H. , A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial, Arthritis & Rheumatism, vol.69, issue.Suppl, pp.2824-2859, 2012.
DOI : 10.1002/art.34498

B. Kuriya, E. Arkema, and V. Bykerk, Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission, Annals of the Rheumatic Diseases, vol.69, issue.7, pp.1298-304, 2010.
DOI : 10.1136/ard.2009.118307

J. Nam, R. S. Gaujoux-viala, and C. , Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.72, issue.3, pp.516-544, 2014.
DOI : 10.1136/annrheumdis-2013-204577

A. Finckh, N. Bansback, and C. Marra, Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents, Annals of Internal Medicine, vol.151, issue.9, pp.612-633, 2009.
DOI : 10.7326/0003-4819-151-9-200911030-00006

G. Van-der-velde, B. Pham, and M. Machado, Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review, Arthritis Care & Research, vol.40, issue.Suppl, pp.65-78, 2011.
DOI : 10.1002/acr.20338

N. Vastesaeger, S. Xu, and D. Aletaha, A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis, Rheumatology, vol.48, issue.9, pp.1114-1135, 2009.
DOI : 10.1093/rheumatology/kep155

J. Sharp, F. Wolfe, and D. Mitchell, The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease, Arthritis & Rheumatism, vol.11, issue.6, pp.660-668, 1991.
DOI : 10.1002/art.1780340606

M. Van-den-broek, L. Dirven, and J. De-vries-bouwstra, Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up, Annals of the Rheumatic Diseases, vol.71, issue.9, pp.1530-1533, 2012.
DOI : 10.1136/annrheumdis-2011-201212

G. Tobón, A. Saraux, and C. Lukas, First-Year Radiographic Progression as a Predictor of Further Progression in Early Arthritis: Results of a Large National French Cohort, Arthritis Care & Research, vol.6, issue.Suppl 1, pp.1907-1922, 2013.
DOI : 10.1002/acr.22078

R. Conroy, K. Pyorala, and A. Fitzgerald, Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project, European Heart Journal, vol.24, issue.11, pp.987-1003, 2003.
DOI : 10.1016/S0195-668X(03)00114-3

J. Kanis, O. Johnell, and A. Oden, FRAX??? and the assessment of fracture probability in men and women from the UK, Osteoporosis International, vol.17, issue.Suppl 2, pp.385-97, 2008.
DOI : 10.1007/s00198-007-0543-5

K. Visser, Y. Goekoop-ruiterman, and J. De-vries-bouwstra, A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study, Annals of the Rheumatic Diseases, vol.69, issue.7, pp.1333-1340, 2010.
DOI : 10.1136/ard.2009.121160

S. Saevarsdottir, H. Rezaei, and P. Geborek, Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial, Annals of the Rheumatic Diseases, vol.73, issue.8, pp.1509-1523, 2015.
DOI : 10.1136/annrheumdis-2013-204601

C. Bombardier, X. Li, and P. Gregersen, A risk model for the prediction of radiographic progression: results from SONORA study, Arthritis Rheum, vol.61, p.276, 2009.

A. Durnez, G. Vanderschueren, and L. Lateur, Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort, Annals of the Rheumatic Diseases, vol.70, issue.4, pp.634-641, 2011.
DOI : 10.1136/ard.2010.135319

B. Fautrel, B. Granger, and B. Combe, Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort, Arthritis Research & Therapy, vol.14, issue.6, p.249, 2012.
DOI : 10.1186/ar4092

URL : https://hal.archives-ouvertes.fr/inserm-00769662

S. Lillegraven, F. Prince, and N. Shadick, FRI0445???The performance of matrix-based risk models for rapid radiographic progression in an observational cohort of established rheumatoid arthritis patients:, Annals of the Rheumatic Diseases, vol.71, issue.Suppl 3, p.1010, 2011.
DOI : 10.1136/annrheumdis-2012-eular.2902

D. Cock, D. Vanderschueren, G. Meyfroidt, and S. , The performance of matrices in daily clinical practice to predict rapid radiologic progression in patients with early RA, Seminars in Arthritis and Rheumatism, vol.43, issue.5, pp.627-658, 2014.
DOI : 10.1016/j.semarthrit.2013.09.004

S. Clair, E. Van-der-heijde, D. Smolen, and J. , Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial, Arthritis & Rheumatism, vol.48, issue.11, pp.3432-3475, 2004.
DOI : 10.1002/art.20568

R. Van-vollenhoven, S. Ernestam, and P. Geborek, Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial, The Lancet, vol.374, issue.9688, pp.459-66, 2009.
DOI : 10.1016/S0140-6736(09)60944-2

Y. Goekoop-ruiterman, J. De-vries-bouwstra, and C. Allaart, Comparison of Treatment Strategies in Early Rheumatoid Arthritis, Annals of Internal Medicine, vol.146, issue.6, pp.406-421, 2007.
DOI : 10.7326/0003-4819-146-6-200703200-00005

B. Combe, J. Benessiano, and F. Berenbaum, The ESPOIR cohort: A ten-year follow-up of early arthritis in France, Joint Bone Spine, vol.74, issue.5, pp.440-445, 2007.
DOI : 10.1016/j.jbspin.2007.06.001

B. Combe and N. Rincheval, Early lessons from the recent-onset rheumatoid arthritis cohort ESPOIR, Joint Bone Spine, vol.82, issue.1, pp.13-17, 2015.
DOI : 10.1016/j.jbspin.2014.07.003

M. Prevoo, M. Van-'t-hof, and H. Kuper, Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.20, issue.1, pp.44-52, 1995.
DOI : 10.1002/art.1780380107

J. Fries, P. Spitz, and D. Young, The dimensions of health outcomes: the Health Assessment Questionnaire, Disability and Pain Scales, J Rheumatol, vol.9, pp.789-93, 1982.

M. Pencina, D. Rbsr, D. Agostino, and R. Jr, Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond, Statistics in Medicine, vol.25, issue.2, pp.157-72, 2008.
DOI : 10.1002/sim.2929

B. Fautrel, B. Combe, and N. Rincheval, Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data, Annals of the Rheumatic Diseases, vol.71, issue.3, pp.386-395, 2012.
DOI : 10.1136/annrheumdis-2011-200259

URL : https://hal.archives-ouvertes.fr/hal-00790235

B. Combe, N. Rincheval, and J. Benessiano, Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort, The Journal of Rheumatology, vol.40, issue.10, pp.1650-1657, 2013.
DOI : 10.3899/jrheum.121515

URL : https://hal.archives-ouvertes.fr/hal-00933273

H. Rezaei, S. Saevarsdottir, and K. Forslind, In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial, Annals of the Rheumatic Diseases, vol.71, issue.2, pp.186-91, 2011.
DOI : 10.1136/annrheumdis-2011-200038

V. Vesperini, C. Lukas, and B. Fautrel, Association of Tobacco Exposure and Reduction of Radiographic Progression in Early Rheumatoid Arthritis: Results From a French Multicenter Cohort, Arthritis Care & Research, vol.123, issue.Suppl, pp.1899-906, 2013.
DOI : 10.1002/acr.22057

D. Van-der-heijde, A. Van-der-helm-van-mil, and D. Aletaha, EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria, Annals of the Rheumatic Diseases, vol.72, issue.4, pp.479-81, 2013.
DOI : 10.1136/annrheumdis-2012-202779

P. Eastman, W. Manning, and F. Qureshi, Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis, Journal of Pharmaceutical and Biomedical Analysis, vol.70, pp.415-439, 2012.
DOI : 10.1016/j.jpba.2012.06.003

W. Li, E. Sasso, and D. Emerling, Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use, Current Medical Research and Opinion, vol.29, issue.1, pp.85-92, 2013.
DOI : 10.1185/03007995.2012.753042

J. Smolen and D. Aletaha, Forget personalised medicine and focus on abating disease activity, Annals of the Rheumatic Diseases, vol.72, issue.1, pp.3-6, 2013.
DOI : 10.1136/annrheumdis-2012-202361

C. Allaart, Y. Goekoop-ruiterman, and J. De-vries-bouwstra, FARR study group Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study, Clin Exp Rheumatol, vol.24, pp.77-82, 2006.

M. Soubrier, X. Puechal, and J. Sibilia, Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial, Rheumatology, vol.48, issue.11, pp.1429-1463, 2009.
DOI : 10.1093/rheumatology/kep261

URL : https://hal.archives-ouvertes.fr/hal-00617943